HVAX
Get Exposure to the Companies Leading Vaccine Development
Horizons Global Vaccines and Infectious Diseases Index ETF (HVAX), allows investors to gain exposure to the potentially long-term theme of vaccine development and disease prevention.
Key Features
• Provides globally diversified exposure to leading companies that provide research, medicines and vaccines against infectious diseases
• Massive public and private investment during COVID-19 pandemic driving exciting innovation in vaccine and pharmaceutical development
• COVID-19 has likely created a long-term focus on global disease prevention, a potentially long-term trend
• Substantial revenue opportunities from further vaccine and infectious disease development beyond COVID-19
Investment Objective
HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.
Fund Details
Ticker
HVAX
Inception Date
October 26, 2021
Net Assets ?
$2,382,014
As at August 12, 2022
Consolidated Prior Day Volume ?
31
For August 12, 2022
Average Daily Trading Volume Over a 12 Month Period ?
495
As at August 12, 2022
Exchange
Toronto Stock Exchange
Investment Manager
Horizons ETFs Management (Canada) Inc.
Eligibility
All Registered and Non-Registered Investment Accounts
Bloomberg Index Ticker
SOCGVAXN
Management Fee
0.60%
(Plus applicable sales tax)
Management Expense Ratio ?
0.70%
As at December 31, 2021
Currency
CAD
Currency Hedging
Seeks to hedge the U.S. dollar value of its portfolio to the Canadian dollar at all times
LEI ?
54930023BO8TOEE8TG37
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
Investment fund regulations restrict the presentation of performance figures until a fund reaches its one-year anniversary.
Calendar Year Performance (%) *
Calendar year performance data is not currently available.
Distributions
Distribution data is not currently available.
Sector Allocation
As at July 29, 2022| Health Care | 99.61% |
| Consumer Service | 0.39% |
Geographic Exposure
As at July 29, 2022| United States | 68.25% |
| Germany | 10.03% |
| France | 7.58% |
| Britain | 5.82% |
| China | 5.71% |
| Australia | 2.62% |
Top 10 Holdings
As at August 12, 2022| Security Name | Weight |
|---|---|
| Moderna Inc | 6.10% |
| BioNTech SE - ADR | 5.65% |
| Pfizer Inc | 5.44% |
| Vaxcyte Inc | 5.01% |
| Merck & Co Inc | 4.91% |
| Adaptive Biotechnologies Corp | 4.67% |
| Vir Biotechnology Inc | 4.64% |
| Maravai LifeSciences Holdings Inc Cl A | 4.50% |
| Immunitybio Inc | 4.44% |
| NOVAVAX INC . | 3.92% |
Holdings are subject to change. Download full prior business day: Holdings
Education
Regulatory and Legal
At a Glance
Get Exposure to the Companies Leading Vaccine Development
Horizons Global Vaccines and Infectious Diseases Index ETF (HVAX), allows investors to gain exposure to the potentially long-term theme of vaccine development and disease prevention.
Key Features
• Provides globally diversified exposure to leading companies that provide research, medicines and vaccines against infectious diseases
• Massive public and private investment during COVID-19 pandemic driving exciting innovation in vaccine and pharmaceutical development
• COVID-19 has likely created a long-term focus on global disease prevention, a potentially long-term trend
• Substantial revenue opportunities from further vaccine and infectious disease development beyond COVID-19
Product Facts
Investment Objective
HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.
Fund Details
Ticker
HVAX
Inception Date
October 26, 2021
Net Assets ?
$2,382,014
As at August 12, 2022
Consolidated Prior Day Volume ?
31
For August 12, 2022
Average Daily Trading Volume Over a 12 Month Period ?
495
As at August 12, 2022
Exchange
Toronto Stock Exchange
Investment Manager
Horizons ETFs Management (Canada) Inc.
Eligibility
All Registered and Non-Registered Investment Accounts
Bloomberg Index Ticker
SOCGVAXN
Management Fee
0.60%
(Plus applicable sales tax)
Management Expense Ratio ?
0.70%
As at December 31, 2021
Currency
CAD
Currency Hedging
Seeks to hedge the U.S. dollar value of its portfolio to the Canadian dollar at all times
LEI ?
54930023BO8TOEE8TG37
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Performance & Distributions
Holdings
Sector Allocation
As at July 29, 2022| Health Care | 99.61% |
| Consumer Service | 0.39% |
Geographic Exposure
As at July 29, 2022| United States | 68.25% |
| Germany | 10.03% |
| France | 7.58% |
| Britain | 5.82% |
| China | 5.71% |
| Australia | 2.62% |
Top 10 Holdings
As at August 12, 2022| Security Name | Weight |
|---|---|
| Moderna Inc | 6.10% |
| BioNTech SE - ADR | 5.65% |
| Pfizer Inc | 5.44% |
| Vaxcyte Inc | 5.01% |
| Merck & Co Inc | 4.91% |
| Adaptive Biotechnologies Corp | 4.67% |
| Vir Biotechnology Inc | 4.64% |
| Maravai LifeSciences Holdings Inc Cl A | 4.50% |
| Immunitybio Inc | 4.44% |
| NOVAVAX INC . | 3.92% |
Holdings are subject to change. Download full prior business day: Holdings
Documents
